AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, ...

AnaptysBio (NASDAQ:ANAB), a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, released its Q2 2025 earni ...

Takeda Pharmaceutical Company saw its drug Entyvio (vedolizumab) approved in China by the National Medical Products ...